Hits: 772
Aulos Bioscience to Present at the 39th Annual J.P. Morgan Healthcare Conference
BOSTON, MA, USA and TEL AVIV, Israel I January 8, 2021 I ATP, a leading life sciences venture capital firm, and Biolojic Design, a biotechnology company that computationally designs functional antibodies, today unveiled Aulos Bioscience, a new company that is developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors. ATP has committed $40 million in Series A funding to advance Aulos lead molecule from preclinical stage through clinical proof of concept, with human trials expected to start later this year. ATP created Aulos with Biolojic to develop antibodies with unique properties that we believe hold best-in-class promise among IL-2 targeted therapies, said Michael Ehlers, M.D., Ph.D., Chief Scientific Officer of and venture partner at ATP. Biolojic has designed elegant and impressively simple molecules that redirect
Genetic basis discovered for the higher risk of prostate cancer in black men
Appeared in BioNews 1078
Black men present genetic variations that make them more vulnerable than white men to developing prostate cancer, research has revealed.
Researchers from the Institute of Cancer Research (ICR) in London and the University of Southern California (USC) led the largest and the most diverse genetic analysis ever conducted for a prostate cancer study, comprised of more than 200,000 men from countries including the US, UK, Japan, Sweden and Ghana. Prostate cancer incidence differs across racial and ethnic groups and it is higher in men of African ancestry and lower in Asian men compared with men of European ancestry explained co-leader Professor Rosalind Eeles, professor of oncogenetics at the ICR. In our new study, we ve shown that genetic factors underlie racial and ethnic differences in the incidence of prostate cancer – and by testing for a range of genetic changes, we can
One-Week Radiotherapy Standard for Early Invasive Breast Cancer medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
How race to track mystery gene with links to three cancers saved millions Robin McKie Science Editor
Ten years ago, Tony Herbert developed a lump on the right side of his chest. The clump of tissue grew and became painful and he was tested for breast cancer. The result was positive.
“I had surgery and chemotherapy and that worked,” he said last week. But how had Herbert managed to develop a condition that is so rare in men? Only about 400 cases of male breast cancer are diagnosed every year in the UK compared with around 55,000 in women. A genetic test revealed the answer. Herbert had inherited a pathogenic version of a gene called BRCA2 and this mutation had triggered his condition.
Los principales avances en la lucha contra el cáncer en España lagacetadesalamanca.es - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lagacetadesalamanca.es Daily Mail and Mail on Sunday newspapers.